Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
50%
Ph phase_4
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

completed150%
not_yet_recruiting150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

NCT07485010
completedphase_4

Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia

NCT07369336

Clinical Trials (2)

Showing 2 of 2 trials
NCT07485010Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not Yet Recruiting
NCT07369336Phase 4

Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2